6:40 PM
 | 
Jun 10, 2008
 |  BC Extra  |  Clinical News

Ipsen reports taspoglutide data

Ipsen (Euronext:IPN) said taspoglutide significantly lowered HbA1c levels compared with placebo in a pair of Phase II trials to treat Type II diabetes. In the first trial, in 306 patients, those in the treatment arms received 5, 10, or 20 mg of the glucagon-like peptide-1 (GLP-1) analog weekly or 10 or 20 mg every two weeks. After...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >